Publications by authors named "Emma Lodl"
Introduction: Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic drug monitoring (TDM) has emerged as a dose optimization strategy in patient populations with altered kinetics. Prior literature has demonstrated that patients with FN exhibit augmented renal clearance which may lead to subtherapeutic drug concentrations with standard dosing regimens.
View Article and Find Full Text PDFUpdates in the use of targeted therapies for the treatment of cholangiocarcinoma.
J Oncol Pharm Pract
July 2023
Article Synopsis
- - The text discusses the current treatment landscape for cholangiocarcinoma (CCA), emphasizing that many patients are not surgical candidates and survival with traditional chemotherapy is under 12 months.
- - A systematic review identified four FDA-approved targeted therapies for advanced CCA, including ivosidenib and three FGFR2 inhibitors, which have created new options for treatment and improved patient outcomes.
- - The emergence of these targeted therapies has prompted new research into combination treatments, such as integrating chemotherapy and immunotherapy, enhancing the overall approach to managing CCA.
The treatment of chronic hepatitis C has been revolutionized with the introduction of direct-acting antivirals (DAAs). However, some patients are not cured with first-line treatment. Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination of a polymerase inhibitor, an NS5A inhibitor, and a protease inhibitor with activity against strains of the hepatitis C virus that show resistance to other first-line antiviral regimens.
View Article and Find Full Text PDF